Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK Email:

Slides:



Advertisements
Similar presentations
Chief Science Officer, SENS Foundation
Advertisements

Health, Disease and Survival The Essex Biomedical Sciences Institute Essex Biomedical Sciences Institute Dr Beverley Wilkinson Department of Biological.
Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,
Arguing the scientific feasibility of defeating aging Aubrey D.N.J. de Grey Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK
No matter what your age or health condition, amino acids play central roles both as building blocks of proteins and as intermediates in metabolism. Angioprim.
REGENERATIVE MEDICINE
Dr Aubrey de Grey Chief Science Officer Repairing the aging brain: the SENS approach Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer, SENS Foundation.
The Biomedical Relevance of Microbial Catabolic Diversity John Archer Department of Genetics University of Cambridge
ANGIOPRIM RestoringBalanceTo Your Body ANGIOPRIM Proper Balance Is the Key to Good Health … Angioprim is the Key To balance within your body.
Age Management Relative Impact of Curing Diseases and Slowing Aging.
Exercise Benefits Taken from: busywomensfitness.com.
Biogerontologists’ duty to discuss timescales publicly Aubrey D.N.J. de Grey Department of Genetics, University of Cambridge.
Dr Aubrey de Grey Chief Science Officer Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer, SENS Foundation
Prospects for extending healthy life - a lot Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK
Cellular and Tissue Adaptation
Stem Cells and Regenerative Medicine
Genetic Engineering: Some Basic Concepts. DNA: The Information Carrier.
Gene therapy progress and prospects cancer. Gene Therapy Primary challenge for gene therapy – Successfully delivery an efficacious dose of a therapeutic.
Human Development starts with just 1 cell – the fertilized egg. This cell divides to produce 2 ‘daughter cells’. These daughters divide, and their daughters.
The application of genome-wide association studies of aging in a patient-driven clinical trial outline Melanie Swan, Aaron Vollrath, Cindy Chen & Raymond.
How Genes are Controlled Chapter 11. Human Cells…. All share the same genome What makes them different????
Genetic Engineering © 2014 wheresjenny.com Genetic Engineering.
Biology of Aging as a Basis for Future Treatment of Non-communicable Diseases and Health Care for the Aged Ilia Stambler, PhD Department of Science, Technology.
Is life extension an enhancement? Yes and no and why that’s useful
Picture of Adult Stem Cell. Introduction Diabetes is an illness that affects the metabolism of insulin. About 16 million people are affected by this disease.
 Stem Cells. Understandings  Specialized tissues can develop by cell differentiation in multicellular organisms.  Differentiation involves the expression.
Experimental strategies in the study of Metabolism
More information: DIYgenomics Aging Study Genomics + physical biomarkers + intervention Study segmentOffering tiers.
NOTES – Embryonic Stem Cells and Cloning. What are stem cells? Embryonic Stem Cells – cells present in the early stages of an embryo’s development that.
WELCOME TO CELL PHYSIOLOGY. What is cell physiology- and how does it differ from cell biology??
FINDING THE DISEASE GENES PROGRESS AND PROBLEMS THE HUMAN GENOME MAPPING PROJECT SEEKS TO READ THE FULL SEQUENCE OF THE HUMAN GENOME 3 Billion bases.
The Science Of Aging - Life span in Today 76 (about 60% increase) At this rate life expectancy should be 121 by Future ? Better Nutrition.
The aging phenotype: cellular aspects A&S Jim Lund.
Stem Cells Different kinds of cells. Learning Objectives stem cells are unspecialised cells found in embryos and in some adult tissues such as bone marrow.
The New Science of Life Chapter 24 Great Idea: Our new understanding of genetic mechanisms is leading to enormous technological advances in medicine and.
GENE THERAPY. What is gene therapy? Gene therapy is the introduction of normal genes into cells that contain defective genes.
What is Biotechnology? “a collection of technologies that use living cells and/or biological molecules to solve problems and make useful products”
Human Cloning. Introduction Cloning- the process of making an identical organism through nonsexual means Cloning- the process of making an identical organism.
Using Stem Cells to Treat Disease The first step: establish stem cell lines (large groups of the same cells) Next: turn on specific genes so that the stem.
Dr Aubrey de Grey Chief Science Officer Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer, SENS Foundation
WHAT MAKES US AGE? Life Cycle II. JOHN TURNER AGE 67 AGE 77.
New extramural projects funded by MF Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK
Stem Cells
By: AHMAD SALLEHUDDIN BIN MUKHTARUDDIN D11A001 & ALVIN LEE JIN WEN D11A003.
Lecture (2)Physical Therapy for Geriatrics
Stem Cells By Sugandha Srivastav.
 Definition ◦ It is combination of two Latin words ◦ Pathos meaning disease ◦ Logos meaning study Pathology is a branch of medicine that deals with the.
Production of Eukaryotic Proteins in Bacteria Human insulin, human growth hormone, and other valuable eukaryotic proteins can be produced economically.
Chapter 3: Cell Division
Cell Aging. Aging is generally characterized by the declining ability to respond to stress, increasing homeostatic imbalance and increased risk of aging-associated.
“Diabetes” When blood sugar is out of control. What happens if the body can’t handle carbs normally? One result is diabetes. This can be detected by a.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
Gene Therapy. What is Gene Therapy? Gene Therapy is the insertion of genes into an individual’s cells and tissues to treat a disease. Gene Therapy is.
What should actuaries be doing in the run-up to a post-aging world? Aubrey D.N.J. de Grey Department of Genetics, University of Cambridge Reprints, general.
Oxidative stress, cause of aging and disease! April 21/2016 ATCO.
Healthy Aging. More People Are Living Longer  The population size and shape has been changing in the United States.  In 1950, there were few older adults.
“Vintage people” are possible, just like vintage cars Dr. Aubrey de Grey Methuselah Foundation, Cambridge, UK Website:
STEM CELLS A cell that has the ability to continuously divide and differentiate (develop) into various other kind(s) of cells/tissues. Stem Cell Characteristics:
Production of Eukaryotic Proteins in Bacteria
Discovery: Stem Cell Biology NIH Actions Continue infrastructure award program Characterize cell lines Stimulate more research on basic biology Train.
La nuova biologia.blu Anatomia e fisiologia dei viventi S
SENS Research Foundation
Can we end aging? 林詩茵 邱淑敏 王雅佳 袁樂宜.
Mention the characteristics
Genes Genes play an important role in our physical appearance.
Fundamentals of Aging Has evolution become obsolete? What is aging?
Genes The basic unit of heredity Encode how to make a protein
Production of Eukaryotic Proteins in Bacteria
What is Biotechnology? “a collection of technologies that use living cells and/or biological molecules to solve problems and make useful products”
Genetics of Microbial Biodegradation
Presentation transcript:

Prospects for defeating aging altogether Aubrey D.N.J. de Grey, Ph.D. Chairman and CSO, Methuselah Foundation Lorton, VA, USA and Cambridge, UK Website:

Semi-technical book Out now: $17.79 at Amazon

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

What is aging? Metabolism always causes “damage” Damage eventually causes pathology

Strategies for intervention Gerontology Geriatrics Metabolism Damage Pathology

Problem 1: this is the pathology Alzheimer’s Stroke Sarcopenia Osteoarthritis Hormonal Imbalance Kidney Failure Cancer Heart Disease Diabetes Incontinence Osteoporosis Macular Degeneration Parkinson’s Pneumonia Emphysema Sex Drive … and LOTS more

Problem 2: this is metabolism

If VW Bugs were built to last

Maintained to last

Strategies for intervention Gerontology Engineering Geriatrics Metabolism Damage Pathology Claim: unlike the others, the engineering approach may achieve a large extension of human healthy lifespan quite soon

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

Reasons for the engineering approach - it targets initially inert intermediates (“damage”)

Reasons for the engineering approach - it targets initially inert intermediates (“damage”) - damage is simpler than metabolism or pathology

This is the damage No new type of damage identified since 1982! Seven Deadly Things 1.Junk - Inside Cells 2.Junk - Outside Cells 3.Cells - Too Few 4.Cells - Too Many 5.Mutations - Chromosomes 6.Mutations - Mitochondria 7.Protein Crosslinks

Giving the middle-aged 30 years of extra healthy life: Robust Human Rejuvenation Damage rising with ageIt or its effects reversible by Cell loss, cell atrophyCell therapy, mainly Extracellular junkPhagocytosis by immune stimulation Extracellular crosslinksAGE-breaking molecules/enzymes Death-resistant cellsSuicide genes, immune stimulation Mitochondrial mutationsAllotopic expression of 13 proteins Intracellular junkTransgenic microbial hydrolases Nuclear [epi]mutations (only cancer matters) Telomerase/ALT gene deletion plus periodic stem cell reseeding

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

Giving the middle-aged 30 years of extra healthy life: Robust Human Rejuvenation Damage rising with ageIt or its effects reversible by Cell loss, cell atrophyCell therapy, mainly Extracellular junkPhagocytosis by immune stimulation Extracellular crosslinksAGE-breaking molecules/enzymes Death-resistant cellsSuicide genes, immune stimulation Mitochondrial mutationsAllotopic expression of 13 proteins Intracellular junkTransgenic microbial hydrolases Nuclear [epi]mutations (only cancer matters) Telomerase/ALT gene deletion plus periodic stem cell reseeding

Autophagy in Alzheimer’s Disease Calnexin Dystrophic NeuritesIEM Cat D

Endothelial Cells Lipid-engorged Lysosome Foam Cell

Bioremediation: the concept - Microbes, like all life, need an ecological niche - Some get it by brawn (growing very fast) - Some by brain (living off material than others can't) - Any abundant, energy-rich organic material that is hard to degrade thus provides selective pressure to evolve the machinery to degrade it - That selective pressure works. Even TNT, PCBs…

Xenocatabolism: the concept Graveyards: - are abundant in human remains… - accumulate bones (which are not energy-rich)… - do not accumulate oxysterols, tau etc... - so, should harbour microbes that degrade them - whose catabolic enzymes could be therapeutic

Environmental decontamination in vivo

7-ketocholesterol degradation - a promising start

First MF-funded paper published

7-ketocholesterol M = 400 M 13C = 401 Dione metabolite ? M = 398 M 13C = 399 Hydroxylated dione ? M = 414 M 13C = 415 Culture growing on 7-ketocholesterol: Culture growing on 13 C-labeled 7-ketocholesterol: Stable isotope labeling and LC/MS reveal 7-ketocholesterol metabolites in the culture supernatant

Steps to biomedical application 1)Isolate competent strains; select by starvation 2)Identify the enzymes (mutagenesis, chemistry, genomics) 3)Make lysosome-targeted transgenes, assay cell toxicity 4)Assay competence in vitro (more mutagenesis/selection) 5)Construct transgenic mice, assay toxicity in vivo 6)Assay competence in disease mouse models 7)Test in humans as for lysosomal storage diseases

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

Only 30 years?! Hardly “defeating aging”… Damage rising with ageIt or its effects reversible by Cell loss, cell atrophyCell therapy, mainly Extracellular junkPhagocytosis by immune stimulation Extracellular crosslinksAGE-breaking molecules/enzymes Death-resistant cellsSuicide genes, immune stimulation Mitochondrial mutationsAllotopic expression of 13 proteins Intracellular junkTransgenic microbial hydrolases Nuclear [epi]mutations (only cancer matters) Telomerase/ALT gene deletion plus periodic stem cell reseeding

Reasons for the engineering approach - it targets initially inert intermediates (“damage”) - damage is simpler than metabolism or pathology - repairing damage buys time

Age Reserve 0 0 max frail Progress avoids diminishing returns Fixing half the damage, then 3/4, then 7/8…. - outpaces the so-far-unfixable damage… - maintains healthspan indefinitely

Longevity escape velocity (LEV) The rate at which rejuvenation therapies must improve (following the achievement of RHR) in order to outpace the accumulation of so-far-irreparable damage

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

What rate of progress is realistic? Data

Simulating aging (Phoenix & de Grey, AGE 2007; 29:133) Metabolism ongoingly causes “damage” and Damage eventually causes pathology So…. Simulations of aging (and intervention) should simulate damage accumulation

Results: LEV is very easy Therapies double efficacy only every 42y

Data

What this means: The first 1000-year-old is probably less than 20 years younger than the first 150-year-old

Structure of this talk -Repair versus retardation -Specifics: the seven types of damage -Intracellular junk/medical bioremediation -Longevity escape velocity: concept -Some evidence that LEV is realistic -The Methuselah Foundation

The Methuselah Foundation -$4.5M in Mprize pot -$7M donated/pledged for research -Current research support ~$2M/year -Growth >2x/year since MF’s formation -Ideal budget $100M/year (500 scientists) -Proof of concept (mice) probably <10y away Bottom line: It’s going well, and it’s pretty cheap!

Why I am doing this

Fun Not fun Why I am doing this

Semi-technical book Out now: $17.79 at Amazon